Biocon shares drop 6% after USFDA inspection of Malaysian unit
The OAI status may cause delay or withholding of pending product approvals or supplements from the facility, Biocon says
oai
October 2023
November 2022
Cipla's Goa plant classified as 'Official Action Indicated' by USFDA; stock falls
USFDA may continue to withhold product approvals from this facility till the outstanding observations are resolved, says Cipla.
